Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Heidi J. Einolf
Advertisement
Heidi J. Einolf is director, modeling and simulation, pharmacokinetic sciences, Novartis.
Articles by Heidi J. Einolf
Advertisement
Latest Updated Articles
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic ModelingPublished: March 16th 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
